1. Home
  2. VSTM vs WVE Comparison

VSTM vs WVE Comparison

Compare VSTM & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VSTM

Verastem Inc.

N/A

Current Price

$8.40

Market Cap

731.8M

Sector

Health Care

ML Signal

N/A

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

N/A

Current Price

$3.47

Market Cap

744.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VSTM
WVE
Founded
2010
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
731.8M
744.8M
IPO Year
2011
2015

Fundamental Metrics

Financial Performance
Metric
VSTM
WVE
Price
$8.40
$3.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
19
Target Price
$15.00
★ $18.06
AVG Volume (30 Days)
2.1M
★ 2.9M
Earning Date
11-03-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 17.49
N/A
EPS
N/A
★ N/A
Revenue
★ $30,914,000.00
$3,704,000.00
Revenue This Year
$275.39
$19.21
Revenue Next Year
$55.47
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 209.14
149.43
52 Week Low
$3.43
$3.37
52 Week High
$10.82
$21.73

Technical Indicators

Market Signals
Indicator
VSTM
WVE
Relative Strength Index (RSI) 59.96 25.81
Support Level $7.29 N/A
Resistance Level $8.69 $4.07
Average True Range (ATR) 0.48 0.21
MACD -0.00 -0.00
Stochastic Oscillator 74.50 9.86

Price Performance

Historical Comparison
VSTM
WVE

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: